Adir Et Compagnie

Les Laboratoires Servier

Centre National De La Recherche Scientifique

Universite Claude Bernard – Lyon1

Atofina

Université Grenoble Alpes

Centre National De La Recherche Scientifique-cnrs

Centre Leon Berard

Institut National De La Sante Et De La Recherche Medicale (inserm)

Université De Caen Normandie

Université De Caen Basse Normandie

Produits Chimiques Auxiliaires Et De Synthese

Centre Regional De Lutte Contre Le Cancer Francois Baclesse

Institut De Cancerologie De L'ouest Rene Gauducheau

Centre De Lutte Contre Le Cancer Francois Baclesse

Sylvain Rault

Pierre Renard

Max Robba

Jean-Charles Lancelot

Bruno Pfeiffer

Daniel-Henri Caignard

Michel Boulouard

Beatrice Guardiola

Michelle Devissaguet

Patrick Dallemagne

Marina Kopp

Pierre Lestage

Jean-Guy Bizot-Espiard

Marie-C&eacute;cile Lebrun

Olivier Renault

Renaud Prudent

Peggy Suzanne

Herv E Prunier

Marie P Foloppe

Jean Guillon

Anne-Sophie Voisin-Chiret

Gerard Adam

Alain Pierre

Philippe Delagrange

Ghanem Atassi

Alain F Riondel

Jean-Michel Paul

Marie-Claire Rettori

G Erard Adam

B Eatrice Guardiola-Lemaitre

Laurent Poulain

Laurence Lafanechère

Eric Denarier

Aurélien Lesnard

Marc Billaud

Eric Fontaine

Martine Cordier-bussat

Lauralie Peronne

Jana Sopkova-de Oliveira Santos

Jean-charles Lancelot

Ronan Bureau

Fr&eacute;d&eacute;ric Fabis

Serge Perato

Audrey Vernet

Marcella De Giorgi

Cecile Enguehard

Stéphane Lemaitre

Jean-Christophe Joseph

Regis Pecquet

Michelle Devissague

Jean Charles Lancelot

Fabien Gautier

Philippe Juin

Jade Fogha

Grégory Burzicki

Jana Sopkova-De Oliveira Santos

Gregory Burzicki

Laïla El Kihel

Régis Pecquet

Marc-Antoine Bazin

The invention concerns a compound of formula (I), Formula (I), wherein R, Rand Rare independently selected form the group consisting of: —a hydrogen atom, —a halogen atom, —an alkyl group, linear, cyclic or branched, saturated or unsaturated, possibly substituted, comprising from 1 to 10 carbon atoms, —an acyl group comprising from 1 to 10 carbon atoms, —a carboxyl group, —an amido group comprising from 1 to 10 carbon atoms, and —an imino group, possibly substituted by an alkyl group, linear, cyclic or branched, saturated or unsaturated, and wherein R, R, Rand Rare independently selected form the group consisting of: —a hydrogen atom, —a halogen atom, —a hydroxyl group, —an alkyl group, linear, cyclic or branched, saturated or unsaturated, possibly substituted, comprising from 1 to 10 carbon atoms, —an alkoxy group comprising from 1 to 10 carbon atoms, —an acyl group comprising from 1 to 10 carbon atoms, —a carbonate group from 1 to 10 carbon atoms, —a carboxyl group, and —a cyano group.

Carbazole derivatives sensitizing cells to anti-cancer agents

The invention relates to compounds of formula (I) as follows: (I) wherein Xand X, identical or different, are NRor a sulfur atom, Y is a group (C-C)alkanediyl, Arand Ar, identical or different, are an aryl group optionally substituted by one or several groups selected from a halogen atom, a (C-C) alkyl, —OR, —NRRand —COOR' with Rand R, independently of each other, are a hydrogen atom, a (C--C) alkyl group or a —CORgroup, Rand R′ independently of each other, are a hydrogen atom or a (C-C) alkyl group, and Ris a hydrogen atom or a (C-C)alkyl group, or a pharmaceutically acceptable salt and/or solvate thereof, in particular for use in cancer treatment.

Mitochondrial activity inhibitors targeting tumoral metabolism

The invention relates to compounds of formula (I), and to their therapeutic use in the treatment of cancer: 

Mcl-1 modulating compounds for cancer treatment

The invention relates to novel guanidine derivatives in the cinnamic series of general formula (I):  The invention also relates to the process for preparing said guanidine derivatives and also to synthetic intermediates. Finally, the invention relates to the use of the guanidine derivatives for the preparation of compositions with anti-glycation properties, especially in cosmetology.

Guanidine derivatives in cinnamic series

A compound of formula (I): wherein: R, R, R, Rare defined in the description, its enantiomers, diastereoisomers, tautomers and also addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful as kinase modulators.

Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same

Compounds of formula (I): wherein: its enantiomers, diastereoisomers and also addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful as AMPK activators.

Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same

Compounds of formula (I):wherein: Medicinal products containing the same are useful in the treatment of non-insulin-dependent type II diabetes, obesity, type I diabetes, hyperlipidaemia, hypercholesterolaemia and cardiovascular complications thereof.

Imidazoline compounds

1-aza-2-alky-6-aryl-cycloalkanes

The invention concerns a method consisting in making a mixed (meth)acrylic anhydride of formula (I) by reacting an alkaline (meth)acrylate of formula (II) and a chloroformate of formula (III), carrying out said reaction in an aqueous medium and in the absence of amines, the mol ratio chloroformate (III)/alkaline (meth)acrylate (II) being at least equal to 1.15. R represents H or CH ; R represents an alkyl, alkenyl, aryl, alkaryl or aralkyl residue; and M is an alkaline metal.

Method for making mixed high purity (meth)acrylic anhydrides

1-aza-2-alkyl-6-aryl-cycloalkane compounds

A compound selected from those of formula (I): ##STR1## wherein: R.sub.1 represents hydrogen, halogen, alkyl, nitro, hydroxy, alkoxy, trihaloalkyl, trihaloalkoxy or optionally substituted amino,

8H-thieno-[2,3-b]pyrrolizin-8-one compounds

The present invention relates to compounds of formula (I): ##STR1## wherein A, x, y, R.sub.1, R.sub.2 and R.sub.3 are as defined in the description. The compounds are useful for treating diseases requiring a selective serotonin reuptake site and 5-HT.sub.2c or 5-HT.sub.3 ligand.

Tricyclic oxime ethers

The present invention relates to a compound selected from these of formula (I): ##STR1## in which A and R.sub.1 are as defined in the description, and medicinal product containing the same which is useful for treating a disorder linked to the 5-HT.sub.3 receptors.

Tricyclic pyrrolopyrazine 5-HT.sub.3 -active compounds

Compounds of the general formula (I): ##STR1## where A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are defined in the description. Medicinal products.

Compounds of N-benzoylpyroline

The invention relates to compounds of general formula I: ##STR1## in which: R.sub.1 represents a radical of general formula (Z.sub.0), (Z.sub.1), (Z.sub.2), (Z.sub.3) or (Z.sub.4) ##STR2## R.sub.2 represents a methylene radical, a hydroxymethylene radical, a carbonyl radical or a radical of general formula (Y.sub.1), (Y.sub.2), (Y.sub.3) or (Y.sub.4): ##STR3## or, with R.sub.12 and the nitrogen atom to which they are attached, forms a radical of general formula (W): ##STR4## R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12 and n being as defined in the description, medicinal products containing the same and a method-of-treating metabolic ailments therewith.

Pyrrolo [1,2-a] thieno [3,2-f] (1,4) diazepines

Growing community of inventors

Moult, France

Sylvain Rault